US FDA is vowing a crackdown on "unscrupulous actors" in the regenerative medicine industry as part of a policy that could also benefit honest manufacturers.
Coming on the heels of a series of recent enforcement actions against stem cell centers in Florida and California, agency...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?